{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T09:32:03Z","timestamp":1789810323341,"version":"4.0.1"},"reference-count":59,"publisher":"American Society for Microbiology","issue":"2","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2014,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p><jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Candida<\/jats:named-content>species are the cause of 60% of all mycoses in immunosuppressed individuals, leading to \u223c150,000 deaths annually due to systemic infections, whereas the current antifungal therapies either have toxic side effects or are insufficiently efficient. We performed a screening of two compound libraries, the Enzo and the Institute for Molecular Medicine Finland (FIMM) oncology collection library, for anti-<jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Candida<\/jats:named-content>activity based on the European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines. From a total of 844 drugs, 26 agents showed activity against<jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Candida albicans<\/jats:named-content>. Of those, 12 were standard antifungal drugs (SADs) and 7 were off-target drugs previously reported to be active against<jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Candida<\/jats:named-content>spp. The remaining 7 off-target drugs, amonafide, tosedostat, megestrol acetate, melengestrol acetate, stanozolol, trifluperidol, and haloperidol, were identified with this screen. The anti-<jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Candida<\/jats:named-content>activities of the new agents were investigated by three individual assays using optical density, ATP levels, and microscopy. The antifungal activities of these drugs were comparable to those of the SADs found in the screen. The aminopeptidase inhibitor tosedostat, which is currently in a clinical trial phase for anticancer therapy, displayed a broad antifungal activity against different<jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Candida<\/jats:named-content>spp., including<jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Candida glabrata<\/jats:named-content>. Thus, this screen reveals agents that were previously unknown to be anti-<jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Candida<\/jats:named-content>agents, which allows for the design of novel therapies against invasive candidiasis.<\/jats:p>","DOI":"10.1128\/aac.01087-13","type":"journal-article","created":{"date-parts":[[2013,11,26]],"date-time":"2013-11-26T03:28:07Z","timestamp":1385436487000},"page":"1055-1062","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":61,"title":["Antifungal Application of Nonantifungal Drugs"],"prefix":"10.1128","volume":"58","author":[{"given":"Marios","family":"Stylianou","sequence":"first","affiliation":[{"name":"Department of Clinical Microbiology, Ume\u00e5 University, Ume\u00e5, Sweden"},{"name":"Laboratory for Molecular Infection Medicine, Sweden (MIMS) and Ume\u00e5 Centre for Microbial Research, Ume\u00e5 University, Ume\u00e5, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgeny","family":"Kulesskiy","sequence":"additional","affiliation":[{"name":"Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Pedro","family":"Lopes","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology, Ume\u00e5 University, Ume\u00e5, Sweden"},{"name":"Laboratory for Molecular Infection Medicine, Sweden (MIMS) and Ume\u00e5 Centre for Microbial Research, Ume\u00e5 University, Ume\u00e5, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margareta","family":"Granlund","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology, Ume\u00e5 University, Ume\u00e5, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krister","family":"Wennerberg","sequence":"additional","affiliation":[{"name":"Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantin F.","family":"Urban","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology, Ume\u00e5 University, Ume\u00e5, Sweden"},{"name":"Laboratory for Molecular Infection Medicine, Sweden (MIMS) and Ume\u00e5 Centre for Microbial Research, Ume\u00e5 University, Ume\u00e5, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67381-3"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2006.01.002"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1086\/591033"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-006-0159-2"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/myc.12013"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2011.11.001"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01079-10"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2004.05.008"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)80358-X"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0811994106"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.2217\/fmb.10.51"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/205921"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0032952"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.169.4.379"},{"key":"e_1_3_2_16_2","first-page":"345","article-title":"Antifungal agents and immunomodulators in systemic mycoses","volume":"42","author":"Khan ZK","year":"2000","unstructured":"KhanZKJainP. 2000. Antifungal agents and immunomodulators in systemic mycoses. Indian J. Chest Dis. Allied Sci. 42:345\u2013355.","journal-title":"Indian J. Chest Dis. Allied Sci."},{"key":"e_1_3_2_17_2","volume-title":"Medical microbiology","author":"Dixon DM","year":"1996","unstructured":"DixonDMWalshTJ. 1996. Chapter 76: antifungal agents. In BaronS (ed), Medical microbiology, 4th ed. University of Texas Medical Branch at Galveston, Galveston, TX.","edition":"4"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/46.2.171"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1R020"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-13-0350"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2012.03880.x"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1000151"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2011.585756"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.6295"},{"key":"e_1_3_2_25_2","volume-title":"Dictionary of Pharmacological Agents","author":"Ganellin CR","year":"1997","unstructured":"GanellinCRTriggleDJMacdonaldF. 1997. Dictionary of Pharmacological Agents. Chapman & Hall, London, United Kingdom."},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/EC.00314-12"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.7164\/antibiotics.28.727"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.3390\/molecules15042203"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1222236"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/172.4.1153"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000639"},{"key":"e_1_3_2_32_2","volume-title":"qHTS assay for small molecule inhibitors of mitochondrial division or activators of mitochondrial fusion. PubChem BioAssay AID 485298","author":"Nunnari JM","year":"2010","unstructured":"NunnariJM. 2010. qHTS assay for small molecule inhibitors of mitochondrial division or activators of mitochondrial fusion. PubChem BioAssay AID 485298. National Center for Biotechnology Information, Bethesda, MD. http:\/\/pubchem.ncbi.nlm.nih.gov\/assay\/assay.cgi?aid=485298."},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0007-117X(82)80026-7"},{"key":"e_1_3_2_34_2","first-page":"249","article-title":"Disappearance of nystatin resistance in Candida mediated by ergosterol","volume":"117","author":"Mas J","year":"1980","unstructured":"MasJPi\u00f1aE. 1980. Disappearance of nystatin resistance in Candida mediated by ergosterol. J. Gen. Microbiol. 117:249\u2013252.","journal-title":"J. Gen. Microbiol."},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0507.1991.tb00623.x"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/EC.3.4.919-931.2004"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1139\/w04-095"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-6627"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.11.3162-3170.2001"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2008.04.019"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-006-9002-1"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.3314\/jjmm.48.109"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1021\/np050074u"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01564-08"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199937060-00001"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/0039-128X(94)00036-C"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2013.01.008"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.2165\/00063030-200519030-00004"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(83)90480-1"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1997.tb04318.x"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1080\/10401230591002048"},{"key":"e_1_3_2_52_2","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S0026-895X(25)08945-X","article-title":"In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone","volume":"41","author":"Leysen JE","year":"1992","unstructured":"LeysenJEJanssenPMGommerenWWynantsJPauwelsPJJanssenPA. 1992. In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone. Mol. Pharmacol. 41:494\u2013508.","journal-title":"Mol. Pharmacol."},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300027"},{"key":"e_1_3_2_54_2","first-page":"463","article-title":"A controlled evaluation of trifluperidol: a new potent sychopharmacologic agent","volume":"5","author":"Gallant DM","year":"1963","unstructured":"GallantDMBishopMPTimmonsESteeleCA. 1963. A controlled evaluation of trifluperidol: a new potent sychopharmacologic agent. Curr. Ther. Res. Clin. Exp. 5:463\u2013471.","journal-title":"Curr. Ther. Res. Clin. Exp."},{"key":"e_1_3_2_55_2","first-page":"243","article-title":"Treatment of aplastic anaemia with methenolone, stanozolol and nandrolone. A report of 130 cases","volume":"23","author":"Resegotti L","year":"1981","unstructured":"ResegottiLDolciCBerteroLGenoveseAPodest\u00e0FTestaD. 1981. Treatment of aplastic anaemia with methenolone, stanozolol and nandrolone. A report of 130 cases. Panminerva Med. 23:243\u2013248.","journal-title":"Panminerva Med."},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(87)80277-4"},{"key":"e_1_3_2_57_2","first-page":"57P","article-title":"The metabolism of melengestrol acetate","volume":"104","author":"Cooper JM","year":"1967","unstructured":"CooperJMElceJSKellieAE. 1967. The metabolism of melengestrol acetate. Biochem. J. 104:57P\u201358P.","journal-title":"Biochem. J."},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.domaniend.2004.07.002"},{"key":"e_1_3_2_59_2","first-page":"15","article-title":"Megestrol acetate: first-line therapy for advanced breast cancer","volume":"13","author":"Johnson PA","year":"1986","unstructured":"JohnsonPABonomiPDAndersonKMWolterJMEconomouSG. 1986. Megestrol acetate: first-line therapy for advanced breast cancer. Semin. Oncol. 13:15\u201319.","journal-title":"Semin. Oncol."},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19820201)49:3<413::AID-CNCR2820490303>3.0.CO;2-S"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01087-13","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01087-13","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T23:10:50Z","timestamp":1746054650000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01087-13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":59,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["10.1128\/AAC.01087-13"],"URL":"https:\/\/doi.org\/10.1128\/aac.01087-13","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"2013-05-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-11-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-01-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}